Blood transfusion following cardiac surgery Surgery Cardiac surgery
Conditions
Interventions
Patients will be randomised to either the cell saver or control group. A Continuous Auto-Transfusion System (CATS, Fresenius Hemocare) cell saver will be used intra- and post-operatively with the aim
Sponsors
Papworth Hospital NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients for non-emergency first-time Coronary Artery Bypass Grafting (CABG) with planned use of cardiopulmonary bypass, and patients for valve repair or replacement, or combined CABG and valve procedure.
Exclusion criteria
Exclusion criteria: 1. Refusal to receive blood or blood products 2. Previous cardiac or thoracic surgery 3. Having an unacceptable risk, as per investigator judgement 4. Known serious coagulation disorders 5. Known blood disorder (thalassemia, chronic anaemia, lymphoproliferative disorder etc.) 6. Any contra-indication to antifibrinolytics 7. The receipt of any investigational drug or participation in a device trial during the course of this trial 8. Where a specific request for cell salvage has been made by the surgeon
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients exposed to allogeneic blood. All outcomes measured at 30 days post surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The number of units of allogeneic red blood cells transfused during first-time cardiac surgery 2. The use of blood products such as fresh frozen plasma and platelet concentrates 3. Adverse events 4. Resource use and cost savings of using CATS in this specific group of patients All outcomes measured at 30 days post surgery. | — |
Countries
United Kingdom
Outcome results
None listed